Dr Stefan Artlich
Director Track&Trace | Bayer AG
Being a mathematician and chemical engineer by profession Stefan is involved in pharmaceutical serialization since its early days in 2008 and renowned as one of the fathers of the European ‘Point-of-Dispense Verification’ model that ensures patients’ access to safe medicines.
For more than seven years Stefan worked as a delegate consultant for the European Federation of Pharmaceutical Industries and Associations (EFPIA) where he contributed to the successful verification pilot in Sweden in 2009 / 2010 and played a key role in the design and development of the European Medicines Verification System (EMVS) that constitutes a key component in the implementation of the EU Falsified Medicines Directive (FMD).
Once having returned from Brussels Stefan led Bayer’s activities to implement the Brazilian Track&Trace requirements in 2014 and 2015 before his focus shifted back to the roots as the responsible program manager for the timely FMD readiness of Bayer’s Pharmaceuticals and Consumer Health divisions.
In 2016, Stefan Artlich was elected member of the Leadership Team of GS1 Healthcare who as a voluntary, global Healthcare User Group engage into integrating GS1 Standards into supply chain processes to drive patient safety and supply chain efficiency improvements.
Director, Public Policy Europe & Canada | MSD
Boris Azaïs is currently Director, Public Policy Europe for MSD (a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA ).
In his capacity, Boris Azaïs engages with European institutions and governments to promote a policy framework that supports pharmaceutical innovation for European patients. His core interest is at the crossroads of research, health and industrial policy, each playing a critical role in ensuring that science is turned into novel medicines that can help patients live better and healthier lives. As part of his engagement activities, Boris speaks at international conferences, produces studies, and coordinates advocacy activities related to the policy framework that enables pharmaceutical innovation. Boris is also involved in joint advocacy efforts with key stakeholders and patient groups related to specific therapeutic areas, such as Alzheimer’s disease, viral hepatitis, diabetes and HIV/AIDS.
In 2003, Boris Azaïs was seconded for two years to the IFPMA, the association that represents the research-based pharmaceutical companies in Geneva, to support the advocacy work of the IFPMA with Geneva-based governmental and non-governmental organizations. Among various topics, Boris worked on public-private partnerships and R&D for neglected diseases.
Prior to that, Boris Azaïs joined MSD in 1998, as Legal Director for Middle-East & Africa, after a multi-year practice as a corporate lawyer for the firm Cleary, Gottlieb, Steen & Hamilton in Paris.
Project Manager | Irish Medicines Verification Organisation (IMVO)
Leonie Clarke has been Project Manager with the Irish Medicines Verification Organisation (IMVO) since October 2015. She has run her own consultancy since 2006, advising clients in the pharmaceutical and healthcare sector on medicines legislation, industry codes of practice and corporate governance. She started her career with the Irish pharmacy regulator and also has extensive experience in the pharmaceutical industry, including a number of years as Scientific & Regulatory Affairs Manager with the international research-based industry trade association in Ireland, IPHA. Leonie is a former Chairperson of the European Pharmacy Students Association, and President and board member of the Irish pharmacy regulator. She is a pharmacy graduate of Trinity College Dublin and has a Master’s degree by research and diplomas in legal studies, EU law and accounting & finance
Director General | European Healthcare Distribution Association (GIRP)
Monika Derecque-Pois was born in Graz/Austria and holds a master’s degree in Economics from the University of Economics in Vienna, where she specialised in International Trade and Marketing.
Ms. Monika Derecque-Pois is the Director General of GIRP, the European Healthcare Distribution Association, which brings together over 750 pharmaceutical full-line wholesaling companies and their national associations from 35 countries. Monika was appointed to her current position in 2001, having previously served as European affairs consultant for GIRP. She has over 20 years of experience in European public affairs.
Prior to her engagement with GIRP, she served as a director in a European affairs consultancy company and she also held a six-year post as Marketing and Client Support Manager at IMS Health Austria.
Global Head of Biopharmaceuticals & Food | State agency of the Department of Jobs, Enterprise and Innovation - IDA Ireland
Tommy Fanning is Head of Bio-Pharmaceuticals and Food department at IDA Ireland, the Irish inward investment agency. His background is in business strategy, development and marketing having held multiple business roles across IDA’s Irish and overseas operations. Prior to his current role he was Head of Engineering, Territory Director for IDA in the US with responsibility for the mid-US states while previously acting as Territory Director for Asia-Pacific based in Tokyo.
He previously worked as Head of Business Development in Europe for Deutsche Bank and State Street in their fund services businesses.
In his current role his team are responsible for building the national strategy as it relates to the development of Bio-Pharma. & Food sectors for international companies in Ireland, as part of the broader life sciences mandate which includes medical technologies.
Having written articles and spoken at conferences on the theme of manufacturing in Ireland, there is now a new window of opportunity for investment in Ireland for high-end manufacturing, value-added services and R&D. Manufacturing is fundamental to the future success of the Irish economy through capital investment and high value job creation with a strong regional focus.
Tommy is a graduate in marketing with a professional qualification from the Marketing Institute of Ireland (MII) and also holds diplomas in business strategy & leadership from the Irish Management Institute (IMI) and accounting & finance from the Assoc. of Chartered Certified Accountants (ACCA).
Secretary General | Pharmaceutical Distributors Federation (PDF)
Seamus Feely works with the Irish Pharmaceutical Distributors Federation as a consultant. Prior to becoming a consultant, Seamus was Secretary General of the Irish Pharmacy Union (IPU) the representative body for the pharmacy sector for over ten years. Prior to taking up his role with the IPU, Seamus held a number of senior roles in the public sector. Seamus looks forward to welcoming delegates to Dublin in May.
Deputy Director General | European Healthcare Distribution Association (GIRP)
Martin FitzGerald is the Deputy Director General for the European Healthcare Distribution Association (GIRP).
Martin’s duties include day to day management, supporting the implementation of the strategic and policy decisions of the associations governing bodies, managing the association’s relations with its member organizations, authorities and other stakeholders. With a legal background, he also deals with the broad range of legislative and regulatory issues affecting pharmaceutical full-line wholesalers as well as healthcare distributors in Europe.
Executive Board Member Operations / Logistics | PHOENIX Group
Frank Große-Natrop was appointed Member of the Executive Board of PHOENIX with responsibility for logistics and operations in February 2014.
From 2010 to 2014, he was Managing Director of PHOENIX’ subsidiary Brocacef Groep NV in the Netherlands. Before this, he held the position of Group Logistics Director within Brocacef Groep (2000 to 2010).
From 1984 to 2000, he worked in various positions for PHOENIX group’s former predecessor companies. Mr. Große-Natrop studied Social Sciences at Cologne University.
President | European Healthcare Distribution Association (GIRP)
Mr. René Jenny was elected the President of the European Healthcare Distribution Association (GIRP) in 2005 and has held this position ever since.
In addition Mr. Jenny is President and Chairman of the Chamber of Commerce and Industry of the Canton of Fribourg, Switzerland and the Swiss wholesalers’ association. He is also member of the Board of several companies. Before starting his career within the Galenica Group, where he held different responsibilities on several management levels, he spent 3 years at the Swiss Scientific Council. René took over the general management of Laboratories Hausmann Plc in 1989 and at the end of 1991 became CEO of Vifor Pharma Ltd.
In parallel René was General Manager for Central Services of the Galenica Group. In 1996 he became the head of the Division Distribution and Services and in 2004 took over the Market division (including the development of eHealth technologies) of the Galenica Group. By mid-2005 he left the Galenica Group in order to spend more time on personal mandates and to become an entrepreneur, he bought the pharma company Interdelta with activities in Switzerland and scaled it to a mid-sized enterprise.
Rene holds a Master Degree in Economics from the University of Fribourg and graduated in 1994 a SEP from Stanford University
(see for details https://www.linkedin.com/pub/ren%C3%A9-jenny/30/ba9/a49).
Senior Director | Excellis Europe
Christoph Krähenbühl, Senior Director at Excellis Europe, has been involved in Serialisation Projects since 2006, as Global Serialisation Project Manager and Product Security Manager at AstraZeneca and as a leading consultant for a many of customers in the pharmaceutical industry.
He brings vast practical experience gained from working with clients in all areas of the industry, from leading global pharmaceutical companies to contract packers, parallel distributors and niche / specialised manufacturers.
Christoph has also been a part of the team readying the industry for the EU-FMD requirements since the beginning and is currently a member of the EMVO Team (European Medicines Verification Organisation). He has been part of the team setting up the EU-Hub onboarding process and is currently supporting the smaller market NMVO project teams.
Vice President Industry Relations | IQVIA
Doug Long is Vice President of Industry Relations at IQVIA, the world’s largest pharmaceutical information company. Doug has been with IMS since 1989. His fundamental task is to help secure data for all existing and new databases supported by IQVIA, manage supplier, manufacturer & association relationships, and develop information for data partners. As direct consequence of his involvement in these areas, Doug has considerable experience with, a unique perspective on, the changing U.S. and global healthcare marketplace and pharmaceutical distribution.
Although well versed in the global pharmaceutical market, the heart of Doug’s Industry year review is that of trends and forecasts in the US. Doug is current on topics such as mergers and acquisitions, tiered co-pay, generics, biologics, PBM’s and other emerging channels, and is also an expert on the complex issue of patient privacy.
Doug was honored with the 2004 HDMA Nexus Award for lifetime achievement and received IMS’s prestigious Summit award in 2003.
Prior to IMS HEALTH, Doug was at Nielsen Market Research for sixteen years in various sales and marketing capacities. A native of Illinois, Doug received a BA degree from the DePaw University in Greencastle, Indiana, and an MBA in Management from Fairleigh Dickinson University in New Jersey.
Deputy Head of Unit, Medical products: quality, safety, innovation | European Commission DG SANTE
Agnès Mathieu-Mendes is Deputy Head of the unit dealing with the quality, safety and innovation of medicinal products in the Directorate General on Health and Food Safety in the European Commission.
Her responsibilities include the implementation of the Falsified Medicines Directive, the Clinical Trials Regulation, Good Manufacturing Practices, Good Distribution Practices and mutual recognition agreements on GMP with third countries. She has been working for many years in the pharmaceutical field notably with the authorisation process of medicinal products or the orphan medicinal products.
Agnès joined the European Commission in 2006 to work on the Better Regulation agenda of the Directorate General for Enterprise and Industry.
She is a pharmacist by training and has a diploma in pharmaceutical engineering and industrial technology. Prior to the European Commission, Agnès held positions in the pharmaceutical industry and in the Council of Europe.
Chief Commercial Officer | Mylan
Tony Mauro is Mylan’s Chief Commercial Officer, overseeing Commercial businesses around the world. As CCO, Tony is responsible for leveraging Mylan’s diverse portfolio, pipeline and expansive commercial infrastructure to drive business growth across multiple markets and channels.
Mauro has been with Mylan for more than 20 years. He has served the company in several capacities of increasing responsibility. Most recently, he served as president of North America, successfully leading the company’s largest commercial business. Prior to that role, Mauro served as president of Mylan Pharmaceuticals Inc., the company's flagship generics division in the U.S.; chief operating officer of Mylan Pharmaceuticals ULC in Canada; vice president of North America Strategic Development; and vice president of North America Sales.
In 2012 and 2013, Mauro served as chairman of the board of directors for the U.S. Generic Pharmaceutical Association (GPhA), which represents the world's leading generic drug manufacturers and suppliers. Prior to that he served two consecutive terms as vice chairman of the board for GPhA, now known as the Association for Accessible Medicines.
Mauro is a member of the visiting committee at West Virginia University's Graduate School of Business and Economics. He earned a bachelor's degree in business administration, with a specialization in finance, and a master's degree in business administration from West Virginia University.
Chief Executive Officer | Irish Business and Employers Confederation (Ibec)
Danny McCoy is CEO at Ibec, the group that represents Irish business domestically and internationally. Since becoming CEO in 2009, he has led a substantial transformation of Ibec increasing turnover to €26 million, leading a professional services staff of 180 in 7 locations and 40 plus sub-brands.
Prior to joining Ibec he was a senior economist at both the Economic and Social Research Institute (ESRI) and the Central Bank of Ireland. He has held lecturing posts at Dublin City University, University College London, University of Oxford and Trinity College Dublin and has been visiting lecturer at the IMD Business School in Switzerland and Harvard University in the US. He has been a consultant for the European Commission and the OECD.
He is a member of the Irish National Competitiveness Council, the National Economic and Social Council and the Export Trade Council. His sits on BusinessEurope Executive Committee and the OECD-BIAC working group on Corporate Taxation.
Danny correctly identified the turnaround in the Irish economy prior to the EU Troika programme and initiated significant media campaigns around the driving the recovery domestically and internationally. Over recent years he has been made significant speeches to the United Nations ILO plenary in Geneva; to the European Business Summit in Brussels; spoken at conferences in the New York and London Stock Exchanges, at the IMF in Washington DC, the World Trade Organisation in Geneva; Hong Kong Chamber of Commerce; Taiwan business summit in Taipei and the OECD Economic Forum in Paris. He regularly presents to the Global Boards of international multinational organisation.
He is a regular contributor in the print and broadcast media and has written columns for the Wall Street Journal, the Financial Times and the Irish Times among other international newspapers. The Irish Times recently described Danny as one of the ‘50 people who runs Ireland’.
Ibec represents Irish business; home grown, multinational, big and small, spanning every sector of the economy. The organisation and its sector associations, work with government and policy makers nationally and internationally, to shape business conditions and drive economic growth. It also provides a wide range of professional services direct to members.
Country Manager | Mylan Ireland
Owen is the Country Manager for Mylan since October 2016. He has assumed the chairman role for Medicines for Ireland since the beginning of May 2018.
Prior to that he has managed Meda Ireland & UK since 2013, having set up the Meda Ireland affiliate in May 2005. He has been in the pharma industry for over 30 years, initially working as sales rep through the managerial role to country manager in 2000 for Provalis.
Policy Manager for Universal Access and Affordable Medicines | European Public Health Alliance (EPHA)
Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines, European Public Health Alliance (EPHA)
Yannis currently leads the advocacy for better and affordable medicines at the European Public Health Alliance (EPHA). Before joining EPHA in January 2016, he worked at the European Parliament, the Greek Ministry of Foreign Affairs, the UN and the private sector in Brussels and Athens. Between 2013-2015, Yannis was Advocacy Advisor for the TransAtlantic Consumer Dialogue (TACD) focusing on access to medicines. Between 2006-2010, he was an investigative reporter for Greece's award-winning TV news programme "Fakeli," and a contributor to the Greek daily "Kathimerini".
Yannis is a founding member of the European Alliance for Responsible R&D and Affordable Medicines and represents the public health voice on the following groups: High Level Group (HLG) to the Round Table meetings for European Health Ministers and Heads of Europe of pharmaceutical companies; Patient and Consumer Working Party (PCWP) of the European Medicines Agency (EMA); Health Technology Assessment (HTA) Network Stakeholder Pool of the European Commission.
He has a Master's degree in International Conflict Analysis from the University of Kent, UK and a Bachelor's degree in European Studies from Pantion University of Social and Political Sciences, Greece. A Greek national, he is fluent in Greek, English and French.
Yannis is committed to promoting transparency, accountability and protecting the public interest in health policy. He contributes to the discussions on regulatory developments in pharmaceuticals, medical innovation and patients’ access to treatment. In January 2018, he was co-opted as a member of the Board of the European Health Forum Gastein (EHFG).
Dr. Lorraine Nolan
Chief Executive | Health Products Regulatory Authority
Ms Nolan is a chemist having completed her Ph.D. and post-doctoral research at Trinity College Dublin in transdermal drug delivery. She worked for a number of years in private industry in the area of enhancing and developing drug delivery systems, and also within the state forensic science services.
Ms Nolan joined the HPRA in 2001 and since that time has held a number of different roles at senior level within the organisation across a range of areas including inspection and authorisation of human medicines, medical devices, cosmetics and controlled substances. Prior to assuming the role of Chief Executive she was Director of Human Products Authorisation & Registration. Ms Nolan is a member of the Management Board of the European Medicines Agency.
Peter O’Donnell is a Brussels-based journalist who has been covering European affairs for more than twenty years. He has worked for The Financial Times, The Sunday Times, Reuters, the Economist Intelligence Unit, UPI, Euronews, and many other media in Europe and beyond, covering all aspects of EU affairs, and conducting television interviews with leading EU figures on issues of the moment. He is a former editor-in-chief of Europe Information Service, and a former associate editor of European Voice and of POLITICO. He is Brussels correspondent for APM Health Europe and European columnist for Applied Clinical Trials. In addition to his work as a journalist, he acts as editor, editorial adviser and speechwriter for numerous clients in the corporate, political and academic world, and has conceived, created and authored numerous publications for the EU institutions and corporate clients. He frequently acts as moderator or chairman in European-level conferences and debates on a wide range of EU-related subjects, at all levels from informal ministerial meetings to specialised seminars and working groups, on subjects ranging from health to ICT, and from foreign affairs to energy.
Secretary General | Irish Pharmacy Union (IPU)
Darragh O’Loughlin is Secretary General of the Irish Pharmacy Union (IPU), the professional representative and leadership organisation for community pharmacists in Ireland. He is also a former President of the IPU as well as a former President of PGEU, the pan-European community pharmacy organisation.
Darragh has experience in both hospital and community pharmacy and has operated his own pharmacies in the west of Ireland for almost 20 years. He received Bachelor’s and Master’s Degrees from Trinity College Dublin and has also gained qualifications from the Institute of Commercial Management and Henley Business School in the UK.
Darragh has wide experience of regulation, quality standards and professional development in pharmacy and healthcare, having previously been appointed by successive Ministers for Health to both the Council of the Pharmaceutical Society of Ireland (PSI) and the Board of the Health Information & Quality Authority (HIQA).
Darragh advocates consistently for a greater recognition of the contribution that community pharmacists make to patient health and for an expansion of the role of pharmacists in delivering convenient, accessible and cost-effective healthcare for the benefit of patients, the public and the health system.
Regional Vice President Europe North and Immunology & HCV lead WE&C | AbbVie
Ryan Quigley was appointed Vice President, Europe North effective February 2017, and expanded his role to also include Immunology & HCV Lead, WE&C in January 2018.
Prior to that, and commencing in 2014, Ryan held the position of Vice President Immunology, Global Marketing for AbbVie, based in Chicago where he oversaw the company’s global immunology marketing and commercial strategy. In this role, he worked to make a remarkable impact on the lives of patients around the world who have been affected by immune-mediated inflammatory diseases.
Before relocating to the US, Ryan was General Manager of AbbVie Ireland. During that time, he was a member of the Irish Pharmaceutical Healthcare Association (IPHA) strategy board. Ryan joined Abbott from Pfizer in 2006 and has also led the immunology franchise in Ireland and in Spain as well as serving as European Commercial Director for immunology based in France.
Ryan is currently a Board Member of the Trinity Biomedical Sciences Institute, where innovative and interdisciplinary approaches are leading to scientific discoveries of biomedical importance.
Ryan is a graduate of the Dublin Institute of Technology and Trinity College Dublin where he received a BSc in Environmental Health and a Masters in Business Administration.
Chief Executive Officer | Uniphar Plc
Ger was appointed CEO of Uniphar Group PLC in March 2010 and in the last 8 years has reshaped the Group, doubling the size of the business and focusing on the expansion of the business in Ireland and into the UK.
An accountant by training, he is a former Managing Director of Movianto and Head of Celesio Solutions and a 25 year veteran of the pharmaceutical sector.
Managing Director | McKesson Ireland
Paul Reilly is the Managing Director of McKesson Ireland with responsibility for United Drug and Lloyds Pharmacy since January 2017. Prior to this he was the Managing Director of United Drug since 2014. He is also a member of McKesson’s European Leadership Team.
He has previously worked with Diageo Ireland in Logistics and in the US for 10 years prior to joining Diageo in both Engineering and Quality Management roles.
He holds a Degree in Industrial Engineering a diploma in Quality Management.
Dr. Severin Schwan
Chief Executive Officer | Roche
Severin Schwan was born in 1967 and is an Austrian citizen. After obtaining a degree in economics and a doctorate in law, Schwan began his career in 1993 at Roche Basel as a finance officer.
Following various management postings to Belgium, Germany and Switzerland, he moved to Singapore as regional head of the Roche Diagnostics business for Asia-Pacific in 2004. In 2006 Severin Schwan became CEO of Roche Diagnostics, the Roche Group’s global diagnostics business.
In March 2008 he was appointed CEO of the Roche Group and he became a member of the Roche Board in 2013. Since 2014 Severin Schwan is also a member of the Board of Directors of Credit Suisse Group AG.
Dr Roger Sorel
Vice President | European Healthcare Distribution Association (GIRP)
Dr Roger Sorel studied at the University of Utrecht where he graduated in Pharmacy in 1977 and graduated with a Doctor of Science degree in 1982. He has since been working as a pharmacist at a health care insurer, and from 1989 he has held management positions at pharmaceutical wholesalers.
He also followed management training at INSEAD, Fontainebleau, France.
From 1 April 1997 until 1 February 2010 he was Managing Director of Brocacef Holding NV.
From 1 August 2010 Dr. Sorel is member of the Supervisory Board of Brocacef Groep NV that is actual a 55/45 joint venture between Phoenix Pharmahandel GmbH & Co KG and McKesson Europe AG.
For many years he was the Chairman of the Dutch Pharmaceutical Wholesale Association (BG Pharma). He still represents BG-Pharma in GIRP where he is Vice President for the smaller and mid sized countries.
In the pharmaceutical area he is the actual Chairman of the Supervisory Board of Farminform BV and Chairman of the Foundation SIR Institute for Pharmacy Practice and Policy.
Besides the pharmaceutical business he is Chaiman of the Dutch General Wholesale Association (NVG) and Board member of the Dutch Employers Organisation (VNO-NCW).
Sales Director Track & Trace | Movilitas Europe
Marco Steinkamp studied Logistics at Fontys University of Applied Science in Venlo (NL). Afterwards he became an employee at British American Tobacco in 2005 and worked here for 10+ years. For approx. 6 years he was a member of local and later also global Supply Chain organization within BAT. For another 4 years he worked in the Global Track & Trace Program in various roles on local and global level e.g. being the responsible Proj Mgr in the Logistics as well as afterwards in the Manufacturing environment.
With this End to End Supply Chain Track & Trace experience and expertise he joined Movilitas Consulting as the European Sales Director for Track & Trace in May 2015. Since beginning of 2017 he’s the Global Sales Director for Track & Trace.
Vice President Strategic Partners | IQVIA
Per Troein has been with IQVIA for 19 years and is responsible for the relationship with suppliers and associations. The dispensing and distribution environment is very dynamic. Pricing of pharmaceutical is as complicated. He also has deep insight around generics and biosimilars and how they are handled in different markets. One of IQVIA’ priorities is to have the best understanding of those dynamics to secure the most appropriate data, to be the best partner with the different data partners, and to be able to support the industry and also when appropriate governments. He is a well know speaker in the field of distribution trends and pricing and is very active in consulting projects in the area.
Prior to joining IMS, Per worked 13 years for Pharmacia in US and Europe. His last 6 years were spent in strategic development as a VP including several major mergers and acquisitions.
He holds an MSc in engineering from Lund’s Institute of Technology and an MBA from INSEAD.
Brian S. Tyler
Chairman of the Management Board (CEO) | McKesson Europe
Brian S. Tyler, Ph.D. is Chairman of the Management Board (CEO) of McKesson Europe, where he focuses on operational excellence, collaboration and innovation to deliver growth across McKesson’s European businesses.
Prior to his current role, Brian served as president, North American Pharmaceutical Distribution Services where he had overall leadership responsibility for McKesson’s pharmaceutical distribution and related businesses in North America including McKesson U.S. Pharmaceutical, McKesson Canada, McKesson Specialty Health and McKesson Pharmacy Systems & Automation. In this role, he worked closely with Celesio to maximize operational excellence and facilitate collaboration across McKesson’s respective pharmaceutical distribution businesses worldwide.
Brian was previously executive vice president of Corporate Strategy and Business Development where he led the overall corporate strategy for McKesson. Brian helped guide strategy development with McKesson’s business unit leaders, in addition to fostering innovation and leading the mergers and acquisitions function across the company.
A 20-year McKesson veteran, Brian was previously responsible for McKesson’s U.S. Pharmaceutical business where he oversaw the business unit’s operations and the distribution of pharmaceuticals and other healthcare related products to customers in four primary segments: national and regional retail pharmacy chains, retail independent pharmacies, hospital providers and mail pharmacy. He previously ran McKesson’s Medical-Surgical business, the nation’s largest alternate site distributor to physician offices, long term care facilities, surgery centers, direct to patient home care and occupational health and employers. Additionally, Brian served as president of McKesson Specialty Care Solutions with responsibility for Specialty Distribution, Specialty Pharmacy, Specialty Marketing Services, Specialty Logistics, and Prospective Health, Inc. Brian has also served as senior vice president of strategy and business development for McKesson Distribution Solutions.
Prior to joining McKesson, Brian spent three years at Integral, Inc. as a Senior Associate, Health Care Consulting in Cambridge, MA. Brian earned his Ph.D. and MA from the University of Chicago, Department of Economics where he studied under a grant from the National Science Foundation. His specializations included Industrial Organization, Labor Economics, and Public Finance/Project Evaluation. Brian earned his B.A. in Economics with High Honors from University of California Santa Cruz.
Brian works in Stuttgart, Germany and lives in London with his wife Kristen and their sons Dylan (6) and Jack (2).
Director Life Science, EMEA | Adents
Hitesh Varambhia has over 15 years of experience across the Life Science and Health Care Management Industry. He has created, shaped and implemented strategies to develop world class solutions through the leadership of People, management of Projects, and Product Portfolio life cycles within Pharmaceuticals, Biotechnology, FMCG, Healthcare and Life Science. Working on complex, global supply chain programs that require the redefinition of global supply chains, global organizations, their processes and management systems. Specifically, in Supply Chain, Manufacturing & Packaging Operations, R&D, Procurement, Transformational Change, Serialization, track and trace, Risk and Commercialisation.
Based in the UK, with broad experience in Europe, Asia (India, China & Japan), North and South America.
Hitesh is one of a few people, who have the breadth and depth of experience, and technical knowledge of Value Chains across Research, Drug Development, Quality, Risk Management, and Compliance, thought to Marketing and Commercial Operations, this enables him to break down organisational boundaries through effective communication, leadership, understanding, collaboration and influencing, building strong effective relationships and partnerships. Prior joining to Adents, Hitesh was serving as Senior Level Executive providing Interim, Advisory Management Consultancy within Procurement, Supply Chain and Commercial Operations divisions. Hitesh is influential across pharma manufacturing and development, and a specialist, having worked in blue chip organisations including Mars Inc. Eli Lilly & Company, Novartis, Philip Morris International, F. Hoffman-La Roche Ltd, and UCB Pharma AG.
"Change before you have to." -Jack Welch
Hitesh is a natural facilitator, leader and empowers the audience to drive to solutions, he thinks of problems as new opportunities to develop innovative solutions. He feels even more motivated when facing tough challenging situations, fueling his passion and drive to overcoming the ‘hardships’ makes him feel successful and content. After all, outstanding people have one thing in common ‘An absolute sense of mission’ our greatest weakness lies in giving up. The most certain way to succeed is always to try just one more time.
Hitesh believes Quality performance starts with a positive attitude and that It’s not about having the right opportunities. It’s about handling the opportunities right.
Hitesh enjoys travelling, reading swimming and cycling, and in those precious moments spending time with his family (his wife and two children).
General Manager | European Medicines Verification Organisation (EMVO)
After his studies of Administration Sciences at the University of Constance in Germany, Andreas M. Walter joined EFPIA, the European Federation of the researched-based pharmaceutical industry, in September 1993 as Executive for Administration and Finance. From 2011 onwards, he was responsible as Project Director to ensure that EFPIA members can comply with the safety features requirements of the Falsified Medicines Directive in the most effective way, i.e. by setting up of a stakeholder-governed pan-European verification model (EMVS). After the incorporation of the European Medicines Verification Organisation (EMVO) in February 2015, he also headed the organisation ad interim in order to manage the European hub that will connect to a series of national data repositories serving as the platform to allow the verification of authenticity of medicines anywhere in the supply chain within the EU/EEA.
On 1st April 2016, he was appointed as General Manager of EMVO representing now definitely the organisation.
Dr. Christa Wirthumer-Hoche
Head | Austrian Medicines and Medical Devices Agency & Chair, European Medicines Agency (EMA) Management Committee
DI Dr. Christa Wirthumer-Hoche studied biochemistry and graduated at the Technical University, Vienna in 1981, she did her doctoral thesis at the Institute for Medical Physiology, graduating in 1983. After joining the Austrian National Institute for Quality Control of Drugs (1983 – 1998), she was the Head of the Licensing Division for medicinal products, in the Unit for Pharmaceutical Affairs at the Austrian Federal Ministry of Health and Women.
Since foundation of the new Austrian Agency 1 January 2006 her position was Head of the Unit for Marketing Authorisation and Lifecycle Management of Medicinal Products, her current position is Head of the Austrian Medicines and Medical Devices Agency at AGES Austrian Agency for Health &Food Safety.
Since 1994 she has been a member in several European Committees and Working Parties, and she is currently appointed Chair of the EMA-Management Board.